Actively Recruiting
Electroacupuncture Treatment for Peripheral Neuropathy After Taxane Chemotherapy in Breast Cancer Patients
Led by Affiliated Hospital of Qinghai University · Updated on 2025-01-14
162
Participants Needed
1
Research Sites
134 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating the use of electroacupuncture as a treatment for peripheral neuropathy caused by taxane chemotherapy in breast cancer patients. This condition can significantly affect the chemotherapy process and patients' quality of life. The study also aims to explore genetic factors related to neuropathy and develop a model to predict outcomes based on certain genetic markers. Participants diagnosed with stage I, II, or IIIA breast cancer who have experienced peripheral neuropathy for at least two weeks will receive electroacupuncture treatment. This method combines traditional acupuncture with mild electrical stimulation at a tolerable intensity. The study groups may be adjusted as needed, and laboratory staff will remain unaware of clinical and outcome details to ensure unbiased results. During the study, participants will be assessed using the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group Neurotoxicity Index (FACT/GOG-NTX) at enrollment and at weeks 4 and 8 of treatment. They will also complete a quality of life questionnaire focused on chemotherapy-induced peripheral neuropathy symptoms. Regular follow-ups and pathological data collection will support monitoring of treatment effects and safety over the course of participation.
CONDITIONS
Official Title
Electroacupuncture Treatment of Peripheral Neuropathy After Taxane Chemotherapy for Breast Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Breast cancer patients diagnosed by pathology
- EOOG score is 0 or 1
- Age between 18 and 75 years old
- Accept chemotherapy regimens based on taxane drugs (alone or in combination)
- Previously received taxane chemotherapy for more than 6 months
- Report chemotherapy-induced peripheral neuropathy symptoms of grade 1 or higher for more than 2 weeks
- Voluntarily participate and sign informed consent
- Accept regular follow-up visits
- Have complete pathological data available
You will not qualify if you...
- Not diagnosed with breast cancer
- Received electroacupuncture treatment within 6 months prior to the study
- Experienced intolerable toxic side effects during standard dose chemotherapy causing termination
- History of peripheral neuropathy before enrollment
- Unstable heart disease or myocardial infarction within 6 months before the study
- Active skin diseases, ulcers, or infections that cannot tolerate electroacupuncture
- Uncontrolled epilepsy with seizures
- Presence of other malignant tumors
- Pregnancy or lactation
- Refusal to join the clinical trial
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Qinghai University Affiliated Hospital
Xining, Qinghai, China, 810001
Actively Recruiting
Research Team
G
Guoshuang Shen G Administrative Director of Breast Center, Affiliated Hospital
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here